Nathan M. Liss

发表

Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.

M. Diamond, Dong-Hua Chen, M. Sherman, 2015, Cell reports.

A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.

J. Roehrig, C. Blair, Nathan M. Liss, 2012, Vaccine.

Characterization of the Bas-Congo Virus Glycoprotein and Its Function in Pseudotyped Viruses

B. S. Schneider, G. Simmons, I. Steffen, 2013, Journal of Virology.

High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014

R. Bruhn, M. Busch, G. Simmons, 2016, Emerging infectious diseases.

Exposure of Epitope Residues on the Outer Face of the Chikungunya Virus Envelope Trimer Determines Antibody Neutralizing Efficacy

David F. Tucker, J. Rucker, G. Simmons, 2014, Journal of Virology.

[PSI+] Maintenance Is Dependent on the Composition, Not Primary Sequence, of the Oligopeptide Repeat Domain

Kacy R. Cobble, Nathan M. Liss, E. Ross, 2011, PloS one.

A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease

A. Suhrbier, David F. Tucker, D. A. Sanders, 2013, PLoS neglected tropical diseases.

Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion.

C. Huang, J. Roehrig, C. Blair, 2013, Virology.

A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

J. Roehrig, J. Schlesinger, C. Blair, 2012, Antiviral research.

A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.

J. Roehrig, C. Blair, Nathan M. Liss, 2012, Vaccine.